Evidence map›Paper›PMID 36850054›Full record

ArticleInternational journal of epidemiology2023

Characteristics and outcomes of an international cohort of 600 000 hospitalized patients with COVID-19.

Christiana Kartsonaki, J Kenneth Baillie, Noelia García Barrio, Joaquín Baruch, Abigail Beane, Lucille Blumberg, Fernando Bozza, Tessa Broadley, Aidan Burrell, Gail Carson and 49 more

Abstract read
In one paragraph

Article in International journal of epidemiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed.

  1. Observational
  2. Article
  3. Observational
  4. Review
  5. Observational
  6. Article
  7. Observational
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

59 authors.

Christiana KartsonakiMedical Research Council (MRC) Population Health Research Unit, Clinical Trials Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.ORCID 0000-0002-3981-3418
J Kenneth BaillieRoslin Institute, University of Edinburgh, Edinburgh, UK.
Noelia García BarrioHospital 12 de Octubre, Madrid, Spain.
Joaquín BaruchInternational Severe Acute Respiratory and emerging Infection Consortium (ISARIC) Global Support Centre, Pandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Abigail BeaneCritical Care Asia, Bangkok, Thailand.
Lucille BlumbergNational Institute for Communicable Diseases, Johannesburg, South Africa.ORCID 0000-0002-6959-5749
Fernando BozzaNational Institute of Infectious Disease Evandro Chagas, Oswaldo Cruz Foundation (INI-FIOCRUZ), Ministry of Health, and D'Or Institute of Research and Education (IDOR), Rio de Janeiro, São Paulo, Brazil.
Tessa BroadleyMonash University, Clayton, Melbourne, Australia.
Aidan BurrellMonash University, Clayton, Melbourne, Australia.
Gail CarsonInternational Severe Acute Respiratory and emerging Infection Consortium (ISARIC) Global Support Centre, Pandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Barbara Wanjiru CitarellaInternational Severe Acute Respiratory and emerging Infection Consortium (ISARIC) Global Support Centre, Pandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Andrew DagensInternational Severe Acute Respiratory and emerging Infection Consortium (ISARIC) Global Support Centre, Pandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Emmanuelle A DankwaDepartment of Statistics, University of Oxford, Oxford, UK.
Christl A DonnellyDepartment of Statistics, University of Oxford, Oxford, UK.
Jake DunningInternational Severe Acute Respiratory and emerging Infection Consortium (ISARIC) Global Support Centre, Pandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Loubna ElotmaniCHU Caremeau, Nîmes, France.
Martina EscherInternational Severe Acute Respiratory and emerging Infection Consortium (ISARIC) Global Support Centre, Pandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Nataly FarshaitHumber River Hospital, Toronto, Canada.
Jean-Christophe GoffardCliniques Universitaires de Bruxelles (CUB) Hopital Erasme, Anderlecht, Belgium.
Bronner P GonçalvesInternational Severe Acute Respiratory and emerging Infection Consortium (ISARIC) Global Support Centre, Pandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Matthew HallBig Data Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Madiha HashmiCritical Care Asia and Ziauddin University, Karachi, Pakistan.
Benedict Sim Lim HengHospital Sungai Buloh, Ministry of Health, Sungai Buloh, Malaysia.
Antonia HoMedical Research Council-University of Glasgow Centre for Virus Research, Glasgow, UK Department of Infectious Diseases, Queen Elizabeth University Hospital, Glasgow, UK.ORCID 0000-0003-1465-3785
Waasila JassatNational Institute for Communicable Diseases, Johannesburg, South Africa.
Miguel Pedrera JiménezHospital 12 de Octubre, Madrid, Spain.
Cedric LaouenanUn iversité de Paris, France, Infection, Antimicrobials, Modelling, Evolution (IAME), INSERM, Paris, France.
Samantha LissauerMalawi-Liverpool Wellcome Trust, Blantyre, Malawi.
Ignacio Martin-LoechesSt James's Hospital, Dublin, Ireland.
France MentréUn iversité de Paris, France, Infection, Antimicrobials, Modelling, Evolution (IAME), INSERM, Paris, France.
Laura MersonInternational Severe Acute Respiratory and emerging Infection Consortium (ISARIC) Global Support Centre, Pandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Ben MortonLiverpool School of Tropical Medicine, Liverpool, UK.ORCID 0000-0002-6164-2854
Daniel MunblitDepartment of Paediatrics and Paediatric Infectious Diseases, Institute of Child's Health, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.ORCID 0000-0001-9652-6856
Nikita A NekliudovSechenov University, Moscow, Russia.
Alistair D NicholIrish Critical Care Critical Clinical Trials Network, Dublin, Ireland.
Budha Charan Singh OinamAll India Institute of Medical Sciences (AIIMS), Rishikesh, India.
David OngFranciscus Gasthuis & Vlietland, Rotterdam, Netherlands.
Prasan Kumar PandaAll India Institute of Medical Sciences (AIIMS), Rishikesh, India.
Michele PetrovicHumber River Hospital, Toronto, Canada.
Mark G PritchardInternational Severe Acute Respiratory and emerging Infection Consortium (ISARIC) Global Support Centre, Pandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Nagarajan RamakrishnanApollo Hospitals Chennai, Chennai, India.
Grazielle Viana RamosNational Institute of Infectious Disease Evandro Chagas, Oswaldo Cruz Foundation (INI-FIOCRUZ), Ministry of Health, and D'Or Institute of Research and Education (IDOR), Rio de Janeiro, São Paulo, Brazil.
Claire RogerCHU Caremeau, Nîmes, France.
Oana SandulescuCarol Davila University of Medicine and Pharmacy, Bucharest, Romania.
Malcolm G SempleInstitute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK.
Pratima SharmaUniversity of Michigan Schools of Medicine & Public Health, Ann Arbor, Michigan, USA.
Louise SigfridInternational Severe Acute Respiratory and emerging Infection Consortium (ISARIC) Global Support Centre, Pandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Emily C SomersUniversity of Michigan Schools of Medicine & Public Health, Ann Arbor, Michigan, USA.
Anca Streinu-CercelCarol Davila University of Medicine and Pharmacy, Bucharest, Romania.
Fabio TacconeCliniques Universitaires de Bruxelles (CUB) Hopital Erasme, Anderlecht, Belgium.
Pavan Kumar VechamApollo Hospitals Chennai, Chennai, India.
Bharath Kumar Tirupakuzhi VijayaraghavanDepartment of Critical Care Medicine, Apollo Hospitals, Chennai, India.
Jia WeiBig Data Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Evert-Jan WilsFranciscus Gasthuis & Vlietland, Rotterdam, Netherlands.
Xin Ci WongNational Institutes of Health (NIH), Ministry of Health, Shah Alam, Malaysia.
Peter HorbyInternational Severe Acute Respiratory and emerging Infection Consortium (ISARIC) Global Support Centre, Pandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.ORCID 0000-0002-9822-1586
Amanda RojekInternational Severe Acute Respiratory and emerging Infection Consortium (ISARIC) Global Support Centre, Pandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Piero L OlliaroInternational Severe Acute Respiratory and emerging Infection Consortium (ISARIC) Global Support Centre, Pandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
ISARIC Clinical Characterisation Group

Funding

CCC for NHLBI Prevention and Early Treatment of Acute Lung Injury PETAL NetworkU01HL123009 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI FOULKES, ANDREA S, THOMPSON, BOYD TAYLOR · 2014 to 2021
$67.2M
Department of Health 200907Department of Health 200927Department of Health CO-CIN-01Department of Health IS-BRC-1215–20013Department of Health NIHR201385Gates Foundation OPP1209135Medical Research Council MC_PC_19026Medical Research Council MC_PC_19059Medical Research Council MR/R015600/1Medical Research Council MR/S032304/1Medical Research Council MR/V001329/1Medical Research Council MR/V001671/1Medical Research Council MR/V030884/1NHLBI NIH HHS U01 HL123009Wellcome TrustWellcome Trust 205228/Z/16/ZWellcome Trust 215091/Z/18/ZWellcome Trust 220757/Z/20/Z
6 · The paper itself

Abstract

backgroundWe describe demographic features, treatments and clinical outcomes in the International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) COVID-19 cohort, one of the world's largest international, standardized data sets concerning hospitalized patients.

methodsThe data set analysed includes COVID-19 patients hospitalized between January 2020 and January 2022 in 52 countries. We investigated how symptoms on admission, co-morbidities, risk factors and treatments varied by age, sex and other characteristics. We used Cox regression models to investigate associations between demographics, symptoms, co-morbidities and other factors with risk of death, admission to an intensive care unit (ICU) and invasive mechanical ventilation (IMV).

resultsData were available for 689 572 patients with laboratory-confirmed (91.1%) or clinically diagnosed (8.9%) SARS-CoV-2 infection from 52 countries. Age [adjusted hazard ratio per 10 years 1.49 (95% CI 1.48, 1.49)] and male sex [1.23 (1.21, 1.24)] were associated with a higher risk of death. Rates of admission to an ICU and use of IMV increased with age up to age 60 years then dropped. Symptoms, co-morbidities and treatments varied by age and had varied associations with clinical outcomes. The case-fatality ratio varied by country partly due to differences in the clinical characteristics of recruited patients and was on average 21.5%.

conclusionsAge was the strongest determinant of risk of death, with a ∼30-fold difference between the oldest and youngest groups; each of the co-morbidities included was associated with up to an almost 2-fold increase in risk. Smoking and obesity were also associated with a higher risk of death. The size of our international database and the standardized data collection method make this study a comprehensive international description of COVID-19 clinical features. Our findings may inform strategies that involve prioritization of patients hospitalized with COVID-19 who have a higher risk of death.

Indexed as

COVID-19ChildHospitalizationHumansIntensive Care UnitsMaleMiddle AgedProportional Hazards ModelsRisk FactorsSARS-CoV-2cohort studyco-morbiditiesCOVID-19risk of deathSARS-CoV-2symptomstreatments

Identifiers

PMID36850054
PMCPMC10114094

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.